INmune Bio, Inc. (INMB)
1.25
+0.04
(+3.31%)
USD |
NASDAQ |
Jun 11, 14:41
INmune Bio Total Assets (Quarterly) : 25.82M for March 31, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 25.82M |
| December 31, 2025 | 32.35M |
| September 30, 2025 | 33.36M |
| June 30, 2025 | 37.68M |
| March 31, 2025 | 37.80M |
| December 31, 2024 | 39.56M |
| September 30, 2024 | 52.78M |
| June 30, 2024 | 52.45M |
| March 31, 2024 | 46.83M |
| December 31, 2023 | 57.00M |
| September 30, 2023 | 62.70M |
| June 30, 2023 | 69.72M |
| March 31, 2023 | 73.98M |
| December 31, 2022 | 81.80M |
| September 30, 2022 | 83.80M |
| June 30, 2022 | 87.81M |
| March 31, 2022 | 94.35M |
| December 31, 2021 | 99.94M |
| September 30, 2021 | 107.67M |
| Date | Value |
|---|---|
| June 30, 2021 | 60.70M |
| March 31, 2021 | 65.87M |
| December 31, 2020 | 40.66M |
| September 30, 2020 | 42.82M |
| June 30, 2020 | 23.05M |
| March 31, 2020 | 23.68M |
| December 31, 2019 | 24.47M |
| September 30, 2019 | 25.40M |
| June 30, 2019 | 27.53M |
| March 31, 2019 | 23.64M |
| December 31, 2018 | 17.36M |
| September 30, 2018 | 17.68M |
| June 30, 2018 | 18.23M |
| March 31, 2018 | 18.83M |
| December 31, 2017 | 18.41M |
| September 30, 2017 | 2.114M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.4516M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Sangamo Therapeutics, Inc. | 59.96M |
| Arrowhead Pharmaceuticals, Inc. | 2.268B |
| Oncolytics Biotech, Inc. | 8.161M |
| Sarepta Therapeutics, Inc. | 3.179B |
| Anixa Biosciences, Inc. | 15.23M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 6.194M |
| Shareholders Equity (Quarterly) | 19.62M |
| Debt to Equity Ratio | 0.0769 |
| Current Ratio | 4.236 |
| Net Debt Paydown Yield | -0.75% |